VXA-G2.4-NS

VXA-G2.4-NS is a monovalent oral tablet vaccine candidate developed by Vaxart for the prevention of norovirus infection caused by the GII.4 strain[1][2][3]. It utilizes a recombinant adenoviral vector (Ad5) to deliver the gene encoding the full-length VP1 protein from norovirus into host cells via an enteric-coated tablet formulation[1]. The mechanism of action is immunostimulation—inducing both systemic and mucosal immune responses against norovirus through oral administration[1][3]. The product is stable at room temperature and designed for ease of use without injection[1]. Clinical development has reached Phase 1/Phase 2 trials in healthy adults and specific populations such as lactating mothers for prevention of noroviral gastroenteritis[1][3].

Other names

VXA-G2.4-NSVXA-G-2.4-NSVXA-G 2.4-NSVXA G2.4 NS